• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 4. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

Introduction to 5,7-Difluoro-1,2,3,4-tetrahydroisoquinoline (CAS No. 939758-81-3)

5,7-Difluoro-1,2,3,4-tetrahydroisoquinoline, identified by its Chemical Abstracts Service (CAS) number 939758-81-3, is a fluorinated derivative of tetrahydroisoquinoline (THIQ), a class of heterocyclic compounds that have garnered significant attention in pharmaceutical and medicinal chemistry due to their diverse biological activities. The introduction of fluorine atoms at the 5 and 7 positions of the THIQ scaffold introduces unique electronic and steric properties, making this compound a promising candidate for further exploration in drug discovery and development.

The structure of 5,7-Difluoro-1,2,3,4-tetrahydroisoquinoline consists of a benzene ring fused to a piperidine ring, with two fluorine atoms substituting hydrogens at specific positions. This modification enhances the compound's lipophilicity and metabolic stability, which are critical factors in the design of bioactive molecules. The presence of fluorine also allows for selective interactions with biological targets, potentially improving binding affinity and selectivity compared to its non-fluorinated counterparts.

In recent years, there has been growing interest in the pharmacological potential of tetrahydroisoquinoline derivatives. These compounds have been shown to exhibit a wide range of biological activities, including neuroprotective, anti-inflammatory, and anticancer effects. The fluorinated derivatives are particularly intriguing due to their ability to modulate enzyme activity and receptor binding more effectively. For instance, studies have demonstrated that fluorinated THIQs can interact with enzymes such as monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), which are involved in the metabolism of neurotransmitters like dopamine and serotonin.

One of the most notable applications of 5,7-Difluoro-1,2,3,4-tetrahydroisoquinoline is in the development of novel therapeutic agents for neurological disorders. Research has indicated that this compound may have potential in treating conditions such as Parkinson's disease and Alzheimer's disease by modulating dopaminergic pathways. The fluorine atoms in its structure contribute to enhanced blood-brain barrier penetration, allowing for more efficient delivery to central nervous system targets. This property is particularly important for therapeutic compounds that need to reach specific brain regions to exert their effects.

The synthesis of 5,7-Difluoro-1,2,3,4-tetrahydroisoquinoline involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Common synthetic routes include Friedel-Crafts alkylation followed by reduction and fluorination steps. Advanced techniques such as transition metal-catalyzed cross-coupling reactions have also been employed to improve synthetic efficiency. The availability of scalable synthetic methods is crucial for the commercial production of this compound for research and therapeutic purposes.

From a medicinal chemistry perspective, 5,7-Difluoro-1,2,3,4-tetrahydroisoquinoline serves as a valuable scaffold for structure-activity relationship (SAR) studies. By systematically varying substituents on the fluorinated THIQ core, researchers can gain insights into how structural modifications influence biological activity. This information is essential for optimizing lead compounds into viable drug candidates. Computational modeling techniques such as molecular dynamics simulations and quantum mechanical calculations are often used in conjunction with experimental data to predict binding affinities and understand interaction mechanisms.

The pharmacokinetic properties of 5,7-Difluoro-1,2,3,4-tetrahydroisoquinoline are another area of active investigation. Fluorine atoms can significantly impact a molecule's half-life by influencing metabolic pathways such as glucuronidation and oxidation. Understanding these effects is crucial for predicting drug efficacy and safety profiles. Preclinical studies have shown that this compound exhibits favorable pharmacokinetic characteristics when tested in animal models, suggesting its potential as a viable therapeutic agent.

In conclusion, 5,7-Difluoro-1,2,3,4-tetrahydroisoquinoline (CAS No. 939758-81-3) represents an exciting avenue in pharmaceutical research due to its unique structural features and promising biological activities. The introduction of fluorine atoms enhances its pharmacological properties, making it an attractive scaffold for developing novel therapeutics targeting neurological disorders among other conditions.* Further research is warranted to fully elucidate its potential applications*and optimize its development into clinical candidates.*

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)